SCAT (Simvastatin/Enalapril Coronary Atherosclerosis Trial)

18 Mar, 14

Purpose

To evaluate the effect of simvastatin on CAD progression in patients with normal levels of cholesterol

Randomized, double-blind, placebo-controlled study .

460 patients with normal levels (4.1-6.2 mmol/L) of cholesterol and established CAD.

Four years

Simvastatin vs. placebo

Simvastatin slowed the progression of CAD.
The need for revascularisation was reduced by 53.6% in the simvastatin group; need for angioplasty was reduced by 61.9%.
Simvastatin caused a greater reduction in lipids as compared to placebo (LDL: 30.9% reduction vs 3.5% increase in placebo group; total cholesterol: 20.7% reduction vs 3.4% increase with placebo; triglycerides: 9.7% reduction vs 8.8% increase with placebo; HDL: 8.2% increase vs 3.1% in placebo).
Addition of enalapril to the treatment regimen had a neutral impact on the progression of CAD.

Simvastatin slows the progression of CAD in patients with normal levels of cholesterol and established CAD

48th Annual Scientific Session of the American College of Cardiology, March 1999